Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1

Conditions

Gastrointestinal Stromal Tumors 71Sarcoma 12Brain Neoplasms 10Gliosarcoma 9Glioblastoma 9Neoplasm Metastasis 6Glioma 6Dermatofibrosarcoma 6Oligodendroglioma 5Central Nervous System Neoplasms 5Astrocytoma 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Fibrosarcoma 4Chordoma 4Sarcoma, Synovial 3Osteosarcoma 3Neurofibrosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Neoplasms 3Liposarcoma 3Hemangiosarcoma 3Glioma, Subependymal 3Digestive System Neoplasms 3Desmoid Tumors 3Sarcoma, Endometrial Stromal 2Recurrence 2Primary Myelofibrosis 2Piebaldism 2Multiple Myeloma 2Meningioma 2

Interventions

Surveys and Questionnaires 3Sunitinib 3Radiosurgery 2Observation 2IDRX-42 2trastuzumab deruxtecan 1repotrectinib 1ponatinib 1pazopanib 1nilotinib 1montanide ISA 51 1atezolizumab 1amminedichloro(2-methylpyridine)platinum(II) 1alectinib 1Transurethral Resection of Prostate 1Sildenafil Citrate 1Radiotherapy 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Oncolytic Virotherapy 1Microscopy, Electron 1Interleukin-2 1Injections 1Imatinib Mesylate 1Drug Therapy 1Doxorubicin 1Cytoreduction Surgical Procedures 1Cryosurgery 1Cisplatin 1CYT-6091 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Imatinib Mesylate × Sarcoma × Clear all
NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
91 enrolled 11 charts
GastrointestinalSarcoma

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡